ClinicalTrials.gg
RecruitingNCT07692984Updated Jul 13, 2026

The Effect of Comorbid Alcohol/Substance Use

An observational study in Alcohol Abuse, Alcohol Use Disorder and Substance Use Disorders, sponsored by Abant Izzet Baysal University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Abant Izzet Baysal University · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
297
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Alcoholism with a site in Turkey — 3 open to participants now, 3 under way, none of them phase 3. Alcoholism · Turkey.

Started
2026
the only one that year
Observational
3 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Abant Izzet Baysal University

Among the 10 studies in Alcoholism with a site in Turkey, this one is the only one that started in 2026, is one of 3 observational ones, and was the 10th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

3 of the 10 studies in Alcoholism with a site in Turkey are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alcoholism with a site in Turkey, or all of them as a file.
02

Study summary

Study Design This study was designed as a comparative, cross-sectional case-control study examining the effect of comorbid alcohol and substance use disorder (ASUD) on clinical course and social inclusion among individuals with severe mental illness followed at a Community Mental Health Center (CMHC). The study did not involve any interventions.

Aim The aim of this study is to examine the effect of comorbid alcohol and substance use on clinical course parameters-such as number of hospitalizations and medication dosages-and on social inclusion indicators-such as employment, social participation, and social adjustment-among individuals with severe mental illness followed at the CMHC, in comparison with a matched control group without substance use.

Research Questions

What are the rates of comorbid alcohol and substance use among patients with severe mental illness followed at the CMHC? What are the current addiction symptoms, number of hospitalizations, and employment rates among individuals with severe mental illness and comorbid ASUD? What is the level of continuity of CMHC engagement and social participation among individuals with severe mental illness and comorbid ASUD, and what factors influence it? How does the level of social inclusion among individuals with severe mental illness and comorbid ASUD compare with that of individuals without ASUD?

Hypotheses

H1: The average annual number of hospitalizations among individuals with a dual diagnosis (severe mental illness + ASUD) followed at the CMHC is significantly higher than among those without substance use.

H2: Among individuals with a dual diagnosis, the daily medication doses (e.g., chlorpromazine equivalents) required to control psychotic or manic symptoms are higher than in the control group.

H3: Social inclusion is lower among patients with substance use compared with the control group.

H4: Employment rates among individuals with a dual diagnosis are significantly lower than among those with severe mental illness alone.

H5: Substance use negatively affects patients' social participation, including involvement in activities and friendships.

H6: Attendance rates at CMHC workshops and rehabilitation programs are lower among individuals with substance use compared with the control group.

Read the detailed description

Study Setting and Sample The study will be conducted at the Bolu İzzet Baysal Mental Health and Diseases Rehabilitation Center , which has a follow-up pool of approximately 1,300 active patients. The study population consists of these 1,300 individuals. The sample size was calculated using Cochran's formula with finite population correction, at a 95% confidence level and a 5% margin of error. This calculation yielded a minimum sample size of 297 individuals. Case and control groups will be distributed in an approximately 1:1 ratio (148 cases, 149 controls).

Data Collection Form

  1. Sociodemographic Variables Age, gender, marital status, education level, living arrangement (living with family/alone/in an institution, etc.), employment status (employed, unemployed, retired, or receiving a disability pension), and social security status.
  2. Clinical Variables

    Primary psychiatric diagnosis (per DSM-5: schizophrenia spectrum disorders or bipolar disorder) ASUD diagnosis and type of substance used (alcohol, cannabis, stimulants, etc.) Duration of illness (in years) Length of follow-up at the Rehabilitation and Treatment Center (in months) Number of psychiatric hospital admissions and total days of hospitalization over the past 2 years Calculated daily chlorpromazine-equivalent (CPZ-eq) dose of antipsychotic and mood-stabilizing medications used Treatment adherence, assessed based on prescription refill frequency and clinical follow-up notes Substance use will be assessed using the Drug Abuse Screening Test (DAST-10) and alcohol use using the Alcohol Use Disorders Identification Test (AUDIT)

  3. Social Inclusion and Rehabilitation Variables

    Attendance rate at TRSM workshops and rehabilitation programs (number of sessions attended / number of sessions planned) Indicators of social adjustment: employment status, independent living skills, and breadth of social network (relationships outside the family) Number of emergency department visits over the past 12 months Social Exclusion (Ostracism) Scale score

  4. Drug Abuse Screening Test (DAST-10) The DAST-10 is a 10-item self-report instrument developed to screen for problems related to the use of substances other than alcohol and tobacco. Developed by Harvey A. Skinner, it assesses substance-related problems over the past 12 months. Items are answered yes/no, with each "yes" scored as 1 point (item 3 is reverse-scored). Total scores range from 0 to 10, with higher scores indicating more severe substance use problems. A Turkish validity and reliability study found an internal consistency coefficient of Cronbach's α = 0.92. That study recommended a cutoff score of ≥4, yielding a sensitivity of 0.98 and specificity of 0.91. The scale is widely used to rapidly screen for substance use problems in clinical and research settings.
  5. Alcohol Use Disorders Identification Test (AUDIT) The AUDIT is a screening instrument developed to identify hazardous and harmful alcohol use. It was developed by Thomas F. Babor and colleagues as part of a multicenter study conducted by the World Health Organization (WHO). The AUDIT consists of 10 items assessing frequency of alcohol use, symptoms of dependence, and alcohol-related problems over the past 12 months. Items are scored on a 0-4 Likert-type scale, yielding a total score range of 0-40, with higher scores indicating more hazardous drinking. A Turkish validity and reliability study confirmed the Turkish version as a valid and reliable measurement tool; a cutoff score of 8 or above is generally accepted to indicate hazardous/harmful alcohol use. The AUDIT is widely used in clinical and research settings for rapid, effective screening of alcohol-related risk. The scale's total possible score is 40, with a cutoff of 8, and its reliability coefficient is 0.65.
  6. Social Exclusion (Ostracism) Scale This is a brief self-report scale developed to assess the frequency of social exclusion (ostracism) experiences in individuals' daily lives. Developed by Sandra C. Rudert and colleagues, it measures exclusion experiences over the preceding two months. The scale consists of 4 items with a unidimensional structure, rated on a 7-point Likert scale (1 = Never, 7 = Always). The total score is calculated by summing item scores, with higher scores indicating more frequent experiences of social exclusion. Confirmatory factor analysis supported a single-factor structure with good model fit (CFI = 0.99, RMSEA = 0.04), and internal consistency was high (Cronbach's α = .90), confirming the scale as a reliable measurement tool.
03

Conditions studied

  • Alcohol Abuse
  • Alcohol Use Disorder
  • Substance Use Disorders
  • Severe Mental Disorder
  • Schizophrenia
  • Bipolar Disorder
  • Ostracism

Keywords

  • alcohol use disorder
  • Substance Use Disorders
  • Severe Mental Disorder
  • ostracism
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with alcohol and substance use disorders among individuals with severe mental illness who are being followed up at the Community Mental Health Center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being 18 years of age or older,
  • Having a diagnosis of Schizophrenia Spectrum Disorder and Other Psychotic Disorders or Bipolar Disorder according to diagnostic criteria,
  • Being actively followed up at the TRSM for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Individuals diagnosed with organic brain damage or neurodevelopmental disorders (intellectual disability, etc.),
  • Individuals with severe cognitive impairment that prevents them from communicating adequately.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
297 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case group

    Patients will be divided into two groups based on whether or not they have a concomitant diagnosis of Alcohol and Substance Use Disorder (ASUD): (1) Dual diagnosis group (Severe Mental Illness + Alcohol and Substance Use Disorder)

    Other: case (comorbid diagnosis)

  • Control group

    (2) Control group (Severe Mental Illness, no Alcohol and Substance Use Disorder). The diagnosis of Alcohol and Substance Use Disorder will be determined according to DSM-5 criteria and the recorded diagnosis in the interview and clinical follow-up notes in the community mental health center physician records.

    Other: control

Interventions

  • Othercase (comorbid diagnosis)

    Patients who already have a comorbid diagnosis of Alcohol and Substance Use Disorder (ASUD) have been exposed to alcohol and substances. Data will be collected by administering the scales to these patients. Social Inclusion and Rehabilitation Variables Substance Use Risk Screening Test (DAST-10) Screening Test for the Diagnosis of Alcohol Use Disorders (AUDIT) Social Exclusion (Ostracism) Scale

  • Othercontrol

    Social Inclusion and Rehabilitation Variables Substance Use Risk Screening Test (DAST-10) Screening Test for the Diagnosis of Alcohol Use Disorders (AUDIT) Social Exclusion (Ostracism) Scale

06

What researchers measure

Primary outcomes

  1. Ostracism

    The level of ostracism will be compared in case and control groups. The effect of alcohol and substance use disorder on the level of ostracism will also be examined.Ostracism will be measured using the "Social Exclusion Scale." The scale is a self-report scale consisting of four items. The minimum score on the scale is 4, and the maximum is 28 points. The total score obtained from the scale will be calculated by summing the items, and higher scores will indicate that the individual experiences social exclusion more frequently. This will show whether the case group or the control group experiences higher levels of ostracism.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Sep 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 9, 2026
StartActual
Jun 20, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07692984
Responsible party
Melisa BULUT (assistant professor, Abant Izzet Baysal University) — Principal investigator
First posted
Jul 9, 2026
Start date
Jun 20, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 13, 2026

Study contacts

Melisa Bulut, PhD
Contact
melisa.bulut@ibu.edu.tr
+905348855882

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion